Company attributes
Industry
Location
CEO
Pitchbook URL
Date Incorporated
2015
Email Address
contact@imvax.com
Phone Number
+12154850071
+12679004110
Full Address
601 Walnut Street, Suite 440W, Philadelphia, PA 19106
Founded Date
2015
Total Funding Amount (USD)
192,370,500
Latest Funding Round Date
July 2020
CFO
Latest Funding Type
Country
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
112,370,500
Imvax's first product, IGV-001, is an autologous tumor cell vaccine that aims to deliver a multi-pronged response against tumor cells by leveraging the patient's immune system as a defense mechanism.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
